The Use of Low Molecular Weight Heparin in Hemodiafiltration
Phase 4
Completed
- Conditions
- Chronic Kidney Disease
- Registration Number
- NCT00756145
- Lead Sponsor
- University Hospital, Ghent
- Brief Summary
Low molecular weight heparin (LMWH) is injected in the dialysis circuit at the start of the session. In the present study we compare 3 different methods of injection of LMWH: parameters of dialysis efficiency and clotting are measured. The study lasts 3 sessions for each patient.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
- chronic kidney disease stade V treated with hemodiafiltration
- age >18 year
- Hematocrit > 30%
Exclusion Criteria
- treatment with vitamin K antagonists
- treatment with other anti-coagulants or heparin besides the heparin used during dialysis
- active bleeding, infection or malignancy
- heparin associated allergy
- hepatic failure
- trombocytopenia < 120.000/µl
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Anti-Xa activity at the end of the session 240 min after start
- Secondary Outcome Measures
Name Time Method Visual inspection of membrane and circuit After the hemodiafiltration session Reduction ratio of beta2microglobulin after 10min, 180min and 240min pressure measurements along the circuit during the session inlet blood line, prefilter, transmembrane, outlet blood line
Anti-Xa activity during the session at start, 30 min, 120 min and 180 min ETP during the session at start, 30 min, 120 min, 180 min and 240 min Reduction ratio of urea after 10min, 180min and 240min
Trial Locations
- Locations (1)
University Hospital Ghent
🇧🇪Ghent, Belgium
University Hospital Ghent🇧🇪Ghent, Belgium